A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of GSK5764227 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
Latest Information Update: 04 Jun 2025
At a glance
- Drugs HS-20093 (Primary) ; Atezolizumab; Bevacizumab; Carboplatin; Cetuximab; Cisplatin; Durvalumab; Fluorouracil; Folinic acid; Pembrolizumab; Topotecan
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
Most Recent Events
- 30 Apr 2025 Trial design presented at the 116th Annual Meeting of the American Association for Cancer Research
- 18 Mar 2025 Fluorouracil and folinic acid removed from the interventions
- 18 Mar 2025 Planned number of patients changed from 240 to 281.